Approximately 20% of patients with TNBC have tumors that highly overexpress EGFR. No targeted therapy is approved for EGFR-overexpressing TNBC. The multicenter, dose-expansion, Phase 2a trial (AVID100-01; NCT03094169)
NMOSD is a rare, life-threatening autoimmune disease affecting the central nervous system. “The Breakthrough Therapy Designation for inebilizumab is based on results from the largest monotherapy study ever
Both firms have announced that top-line results from a phase 3 study assessing tanezumab 2.5mg and 5mg. Tanezumab is an investigational monoclonal antibody, which works by selectively targeting,
Under the terms of the agreement, CASI has obtained global rights to TSK011010 for an upfront payment of 5 million euros and an equity investment of 2 million
DUAKLIR PRESSAIR is a fixed-dose LAMA/LABA combination of the long-acting muscarinic antagonist (LAMA) aclidinium and the long-acting beta agonist (LABA) formoterol. It is administered twice daily via the
As per terms of the deal, twoXAR will apply its AI discovery technology to identify a set of initial candidates to treat lung cancer through novel biological mechanisms
LabCorp said that the proposed deals will make the company to pay a net cash of $485m and will add an incremental $156m to revenues on a pro
The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program. The Centers for Disease Control and Prevention (CDC) estimates that 6-7 million people in
Hyleukin-7 also received ODD from the European Medicines Agency in 2017, and it is the first and only agent that has obtained ODD for ICL. ICL was first
Based in Athens of Greece, Genepharm is involved in the development, manufacturing and out-licensing of high-value generic pharmaceutical products. The company, which owns a wide portfolio of products,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.